Treatment barriers continue to limit provision and uptake of highly effective treatment
for many people with chronic hepatitis C virus (HCV) infection. In the United States,
notable barriers include both patient level (for example, poor access to healthcare,
lack of health insurance, low diagnosis and treatment uptake rates, and fear of discrimination),
and system level (such as costs and administrative rules, including requirements for
prior authorizations, abstinence from substance use and alcohol, and prescriber restrictions,
among others
1
). The high prevalence of HCV infection among PWID (People Who Inject Drugs), globally,
warrants novel approaches to HCV treatment to reduce prevalence and ongoing transmission.
2
The cascade of care, or sequence of steps that individuals must go through to receive
HCV treatment, from diagnosis to sustained virologic response is not promising,3,
4, 5 despite studies showing that PWID with HCV can be engaged and successfully treated
for HCV.6, 7, 8 Notwithstanding the lack of concerted population level approaches
to, progress is being made in small increments by dedicated and creative groups to
test and provide models of care for PWID. In this issue of Lancet Regional Health
- Americas, Lettner et al.,
9
present results from a novel program in Toronto, Canada, that brings together many
of the elements proposed as needed to improve HCV treatment uptake and completion
among PWID: access to testing and medication, integrated care, trust, and community
support.
10
The authors describe the program as low barrier - and although patients did actually
face many barriers, the program provides essential strategies for successful HCV treatment
programs for PWID.
In this study, which was conducted at a Supervised Consumption Service called “keepSIX”,
an HCV treatment program was implemented that offered point-of-care (POC) HCV RNA
testing, on-site providers including nurses and physicians who could conduct pre-treatment
assessments and prescribe and dispense medications. Overall, among 64 participants
who were HCV RNA positive, 89% (57/64) were eligible for treatment, 67.2% (43/64)
were linked to co-located HCV care (intake with the health center's HCV Treatment
Nurse). Of those linked to onsite HCV treatment, 67.4% (29/43) initiated treatment,
and 86.2% (25/29) achieved SVR. Overall, a substantial proportion - 43.9% (25/57)
of those eligible were cured of HCV infection, demonstrating a successful HCV treatment
model. This success is notable since the participants faced many of the same barriers
- especially at the system-level - extant in healthcare systems. The term "low barrier"
is used to describe programs or services that are designed to be easily accessible
and available to individuals who may face obstacles to receiving healthcare, such
as financial or logistical barriers. However, there are situations where a program
or service that is marketed as "low barrier" may not actually be low barrier in practice.
Participants with HCV in this study were still required to have confirmatory HCV RNA
testing from a reference laboratory, and to have two consecutive positive HCV RNA
tests six months apart for confirmation of chronic HCV viremia. Further, the study
was impacted by the COVID-19 pandemic, which challenged healthcare delivery everywhere.
The median time from first positive HCV RNA test to linkage to care was 63 days (IQR:
6–230 days), and the median time between first positive HCV RNA test and treatment
initiation was 265 days (IQR: 177–503 days). Despite these drawbacks, the program
offered key factors necessary for low-barrier HCV treatment access which need to be
highlighted. (1) Physical accessibility: the program was co-located in a space where
PWID could feel safe, access support, engage in harm reduction strategies, and obtain
primary care. Inherent in such a space is trust, which was indeed a motivation for
treatment identified in this study. (2) Cultural competence: an Indigenous Health
Promotor was available at the supervised consumption service creating a culturally
safe healthcare space. As American Indian and Indigenous people are disproportionately
impacted by HCV in the U.S. and Canada,
11
having such a resource can be a pivotal factor for access to and uptake of treatment.
(3) Cost: Since the program was in Canada, where all Canadian residents have reasonable
access to medically necessary hospital and physician services without paying out-of-pocket,
participants received treatment for free.
While POC HCV testing was available, and the authors attributed much success to that,
especially in contributing significantly to identifying people with current HCV infection,
it was not likely the main factor. What is evident was that participants were in a
safe, non-judgmental setting and there was underlying trust. In this case it is important
to look beyond the marketing language of a program or service and consider whether
it is truly accessible and low barrier in practice, especially for individuals who
face multiple barriers to healthcare access. Trust is an essential component of healthcare
and research. It is the foundation of the relationship between patients and healthcare
providers, as well as between researchers and study participants. Without trust, patients
may not feel comfortable sharing their medical history or discussing their concerns,
and study participants may be hesitant to enroll in clinical trials or provide accurate
information. Trust, in healthcare and research, encourages honest communication, increases
adherence to treatment, promotes engagement, increases public support, and promotes
health equity. When people have confidence in the healthcare system and research institutions,
they are more likely to support funding for, and participate in, public health initiatives.
The researchers and providers at the keepSIX supervised consumption service provided
an innovative healthcare delivery model responsive to the needs of a marginalized
and underserved population. Successful HCV treatment for PWID can effectively reduce
incidence of the infection.
12
While national and state programs continue to be considered for HCV elimination efforts,
it may be the villages - like this one at the keepSIX supervised consumption service
that ultimately contribute to real progress.
Disclosures
None.
Declaration of interests
The authors have no interests to declare.